 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical (eye drops) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Plasma |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.007.169 |
| Chemical and physical data | |
| Formula | C16H26N2O3 |
| Molar mass | 294.395 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Proxymetacaine (INN) orproparacaine (USAN) is atopical anesthetic drug of theaminoester group.
Proxymetacaine is a local anesthetic which on topical application penetrates sensory nerve endings in the corneal tissue.[2]
Proxymetacaine is believed to act as anantagonist on voltage-gatedsodium channels to affect the permeability of neuronal membranes; how this inhibits pain sensations and the exact mechanism of action of proxymetacaine are, however, unknown.[3]
Proxymetacaine hydrochloride ophthalmic solution (eye drops) is indicated for procedures such astonometry,gonioscopy, removal offoreign bodies, or other similar procedures requiring topical anesthesia of thecornea andconjunctiva.[4]
Proxymetacaine is for topical ophthalmic use only, and it is specifically not intended for injection. Prolonged use of this or any other topical ocular anesthetic may produce permanentcorneal opacification with accompanyingvisual loss.
Proxymetacaine is available as its hydrochloride salt in ophthalmic solutions at a concentration of 0.5%. Although it is no longer on patent, it is still marketed under thetrade names Alcaine, Ak-Taine, and others. Proparacaine 0.5% is marketed as Poencaina by Poen Laboratories.[5]
